medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 1

<< Back Next >>

Ann Hepatol 2014; 13 (1)

Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment

Caviglia GP, Ciancio A, Rosso C, Abate ML, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M

Language: English
References: 27
Page: 91-97
PDF size: 156.46 Kb.


ABSTRACT

Background. In the management of chronic hepatitis C (CHC) patients, liver biopsy is the gold standard for liver fibrosis assessment despite some technical limits and risks. Non-invasive approaches have been proposed as alternative methods to evaluate structural liver damage. Aim. To investigate the diagnostic accuracy of transient elastography, 13C-aminopyrine breath test (13C-ABT), serum hyaluronic acid (HA) and cytokeratin 18 Asp396 fragment (CK-18) as non-invasive methods of liver fibrosis assessment ad their correlation to METAVIR score. Material and methods. In a cohort of 57 CHC patients, liver stiffness, cumulative percentage of administered dose of 13C-aminopyrine at 120 min, serum HA and serum CK-18 concentration were determined. Diagnostic accuracy in detecting significant fibrosis (F ≥ 2), severe fibrosis (F ≥ 3) and cirrhosis (F = 4) was assessed by the area under the receiver operating characteristic curve. Results. Liver fibrosis score showed a strong correlation with liver stiffness (r = 0.667; p ‹ 0.0001) and a significant inverse correlation with 13C-ABT results (r = -0.418; p = 0.0012). A weaker correlation was found with CK18 (r = 0.329; p = 0.0126) and no correlation with HA. Areas under the curve of elastography, 13C-ABT, HA and CK18 were: 0.98, 0.75, 0.69, 0.64, respectively, for F ≥ 2; 0.97, 0.69, 0.80, 0.66, respectively, for F ≥ 3; 0.95, 0.64, 0.70, 0.56, respectively, for F = 4. Conclusion. Elastography has the best diagnostic accuracy for the assessment of the degree of liver fibrosis in CHC patients. Its application can provide an alternative useful tool for monitoring the disease evolution.


REFERENCES

  1. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of Transient Elastography, Fibrotest, APRI, and Liver Biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroentero 2005; 128: 343-50.

  2. Van Gulick JJ, Lamers MH, Drenth JP. Hepatitis C virus infection management in 2012. Panminerva Med 2012; 54: 1-9.

  3. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94.

  4. Attallah AM, Abdallah SO, Attallah AA, Omran MM, Farid K, Nasif WA, Shiha GE, et al. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. Ann Hepatol 2013; 12: 44-53.

  5. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-9.

  6. Ladero JM. Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C. Hepat Mon 2011; 11: 698-700.

  7. Torok NJ. Recent advantages in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol 2008; 43: 315-21.

  8. Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 2006; 15: 149-59.

  9. Isman FK, Kucur M, Bayal B, Ozkan F. Evaluation of serum hyaluronic acid level and hyaluronidase activity in acute and chronic hepatitis C. J Int Med Res 2007; 35: 346-52.

  10. Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005; 4: 6.

  11. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.

  12. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.

  13. Jazwinski AB, Tompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat 2012; 19: 278-82.

  14. Perri F, Pastore M, Annese V, Andriulli A. The aminopyrine breath test. Ital J Gastroenterol 1994; 26: 306-17.

  15. Giannini E, Fasoli B, Chiarbonello B, Malfatti P, Romagnoli F, Botta F, Testa E, et al. 13C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 717-25.

  16. Castéra L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.

  17. Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, Marzano A, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71.

  18. Actis GC, Olivero A, Lagget M, Pellicano R, Smedile A, Rizzetto M. The practice of percutaneous liver biopsy in a Gastrohepatology day hospital: a retrospective study on 835 biopsies. Dig Dis Sci 2007; 52: 2576-9.

  19. Rocco A, De Nucci G, Valente G, Compare D, D’Arienzo A, Cimino L, Perri F, et al. 13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. J Hepatol 2012; 56: 782-7.

  20. Ziol M, Handra-Luca A, Kattaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.

  21. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based tarnsient elastography for the detection of hepatic fibrosis: systematic reviewand meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214-20.

  22. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Hermann E. Performace of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterol 2008; 134: 960-74.

  23. Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR, Mandalia S, Bower M, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-9.

  24. Parise ER, Oliverira AC, Mendes-Figueiredo C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006; 26: 1095-9.

  25. McHutchison JG, Blatt LM, De Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000; 15: 945-51.

  26. Tamano M, Kojima K, Akima T, Murohisa T, Hashimoto T, Uetake C, Sugaya T, et al. The usefulness of measuring liver stiffness by transient elastography for assessing hepatig fibrosis in patients with various chronic liver diseases. Hepato-Gastroenterol 2012; 59: 826-30.

  27. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-S56.




2020     |     www.medigraphic.com